INSIGHT 01Fact
87%
87% of applications are in Pharmaceuticals
812 applications in this field, 760 of them in IPC A61K — the main axis of the portfolio.
Method: Field applications ÷ applications with IPC
Company patentsInnovative medicines and biopharmaceuticals
COMPANY PATENT INTELLIGENCE
Explore medicines, formulations and related technologies through publications attributed to selected Pfizer legal entities.
≥998docs
83 per month · peak 2025-03 (155)
Empty dashed outlines are uncollected periods, not zero. Dashed bars have partial name or date coverage.
INSIGHT 01Fact
87%
812 applications in this field, 760 of them in IPC A61K — the main axis of the portfolio.
Method: Field applications ÷ applications with IPC
934 applications with IPC codes are mapped to 35 fields using the WIPO IPC–Technology Concordance; area is the number of applications. Select a tile to see its IPC subclasses. An application can belong to several fields.
Publications per month in each field; brighter cells mean more. It shows which directions surge in particular months.
This chart covers collected documents published from 2025-01-01 to 2025-12-31. Examination and publication processes affect this timing; it does not directly measure R&D investment in the same period.
| Technology field | 25-01 | 25-02 | 25-03 | 25-04 | 25-05 | 25-06 | 25-07 | 25-08 | 25-09 | 25-10 | 25-11 | 25-12 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmaceuticals | 54 | 67 | 137 | 69 | 83 | 68 | 75 | 42 | 54 | 84 | 57 | 53 |
| Organic fine chemistry | 21 | 23 | 62 | 29 | 39 | 26 | 28 | 18 | 19 | 24 | 26 | 22 |
| Biotechnology | 24 | 35 | 57 | 28 | 31 | 22 | 26 | 16 | 24 | 31 | 14 | 15 |
| Medical technology | 4 | 3 | 5 | 3 | 3 | 2 | 7 | 3 | 4 | 3 | 4 | 0 |
| Chemical engineering | 3 | 3 | 0 | 2 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 2 |
| Analysis of biological materials | 0 | 1 | 2 | 0 | 1 | 0 | 2 | 0 | 1 | 0 | 2 | 1 |
| Macromolecular chemistry, polymers | 2 | 1 | 1 | 1 | 0 | 2 | 0 | 0 | 1 | 1 | 0 | 0 |
| Computer technology | 3 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 3 | 0 |
Documents in the current publication window are deduplicated by application number and grouped by filing year. These are not the company's complete annual filings; older applications may only be published or granted within this window.
Invention applications are generally published about 18 months after filing, or priority where claimed, and may be published earlier. Flags are estimated as of 2026-11-17. An unflagged year is still not necessarily complete; these counts cannot establish growth or contraction in R&D.
Multi-year evolution · With a longer collection window, this becomes a yearly view that marks the fastest-growing and shrinking fields.
Four reproducible structural ratios, with the other published companies on the same scale. Entity scopes and windows can differ, so read relative positions only — this is not a ranking.
Position 5 of 26 published companies.
Method: Sum of squared field shares
Position 9 of 26 published companies.
Method: Utility model documents ÷ all documents
The source has no CPC codes, so this cannot be computed.
Method: Documents with CPC Y02 ÷ documents with CPC
Position 16 of 26 published companies.
Method: Applications in measurement, chemical engineering, handling and machine tools ÷ all applications
Organisations that filed jointly with the collected entities; line weight represents joint applications. Name-based candidates and reviewed relationships are labeled separately. Co-applications alone do not prove ownership.
Possible affiliation is a review lead only. Co-applicants without a review record are not automatically group members or external partners, and their independent filings are not added to these statistics.
Review the entity listEntity review and data coverage are separate facts. This list shows the current entity configuration, evidence and relationship dates, matched name by name against this snapshot.
Filters change only the entity list below, not the statistics. A complete group snapshot is not available to switch to on this page.
Showing 1 of 1 entities
原始申请人示例将 PFIZER 与 PFIZER INC 对应到 Pfizer Inc.。未纳入 Seagen、惠氏及其他子公司独立名下文献。
Review evidenceRelationship dates help interpret renaming, acquisitions and joint ventures. Missing dates do not establish an indefinite relationship or verify the current patent owner.
Written by editors after reading the patent texts and company materials. Verified facts and inferences are labeled, each with evidence and limits.
Select a theme to filter reviewed patents and observations that cite them. Counts are editorial samples only; one patent may belong to several themes. They do not describe the full portfolio distribution.
Themes describe the technical directions in these samples. Links to adoption in specific products, commercialization or commercial value have not been established.
Showing 2 sample patents · 0 linked observations
Hand-picked documents that illustrate technology themes — not a ranking of core patents and not representative of the whole.
US20250000960A1
The abstract describes RNA encoding an E. coli FimH antigen and lipid-nanoparticle formulations. Claim 1 specifically requires a FimH-encoding open reading frame and a 5′ untranslated region with at least 90% identity to one of the listed sequences. Lipid nanoparticles appear in the abstract but are not a required element of this claim.
US20250009864A1
The abstract concerns pneumococcal capsular glycoconjugates. Claims 1–31 are marked cancelled in this publication, so the reading uses claim 32: a kit containing two immunogenic compositions, each including at least one glycoconjugate from its respective listed serotype group. The two at-least-one requirements do not require every listed serotype.
39 publication offices · 998 documents
Counts use the publication office of each collected document, retaining publications from the same family in different jurisdictions. This is not a map of complete families, granted or active rights; WO and EP denote international and European publication routes.
Invention publication
A crystalline form of 6-fluoro-3-(2,4,5-trifluoro-3-methoxyphenyl)-1-benzothiophene-2-carboxylic acid
PFIZER
Organic fine chemistryPharmaceuticals
Invention publication
Anti-migis-alpha antibodies and methods of use thereof
PFIZER / BENAROYA RES INSTITUTE AT VIRGINIA MASON
BiotechnologyPharmaceuticals
Invention publication
Pyrido[4,3-d]pyrimidine compounds
PFIZER
Organic fine chemistryPharmaceuticals
Invention publication
Self-amplifying rna encoding an influenza virus antigen
PFIZER
BiotechnologyPharmaceuticals
Other
Anticuerpos anti-tl1a y metodos de uso de los mismos
PFIZER / BRISTOL MYERS SQUIBB CO
BiotechnologyPharmaceuticals
Invention publication
Multispecific antibodies and uses thereof
PFIZER
Biotechnology
Invention grant
Chimeric antigen receptors targeting FLT3
PFIZER
BiotechnologyPharmaceuticals
Invention grant
Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof
PFIZER
Organic fine chemistryPharmaceuticals
Invention grant
Modulators of STING (stimulator of interferon genes)
PFIZER
Organic fine chemistryPharmaceuticals
Other
LUC00273I2
PFIZER
Other
LUC00274I2
PFIZER
Other
2-amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors
PFIZER
Organic fine chemistryPharmaceuticals
Other
Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer
PFIZER / ASTELLAS PHARMA INC
Pharmaceuticals
Other
Inhibidores de acc novedosos
PFIZER
Organic fine chemistryPharmaceuticals
Other
Moléculas de rna que codifican rsv-f y vacunas que las contienen
PFIZER
BiotechnologyPharmaceuticals
Invention publication
Chimeric antigen receptors targeting cd70
PFIZER
Medical technologyBiotechnologyPharmaceuticals
Invention publication
Tissue factor pathway inhibitor antibodies and uses thereof
PFIZER
BiotechnologyPharmaceuticals
Invention publication
Toll-like receptor agonists and conjugates thereof
PFIZER
Organic fine chemistryPharmaceuticals
Other
Derivados de pirrolopiridina y su uso en el tratamiento de una infeccion por rsv
PFIZER
Organic fine chemistryPharmaceuticals
Invention grant
Treatment of type 2 diabetes with 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl} piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof
PFIZER
Pharmaceuticals
Titles come from the source bibliography. Select a number to read the full document on this site.
Upload your invention disclosure and get an editable draft that follows CNIPA practice.
Publications are deduplicated by publication number; applications by application number, so a publication and its grant count once; families by the source family ID. Technology fields are derived automatically from IPC codes using the WIPO IPC–Technology Concordance (March 2026), without manual or AI labeling.
Publication or grant documents do not establish current rights. Check legal status and current owners with the relevant patent office.
These statistics use only the applicant names and publication dates collected for this snapshot. They do not represent the full company or group portfolio.
The reviewed entities and aliases below describe the current company configuration. Only names listed above are covered by this snapshot.
Pfizer Inc.
Configured aliases: PFIZER · PFIZER INC
Original review note: 原始申请人示例将 PFIZER 与 PFIZER INC 对应到 Pfizer Inc.。未纳入 Seagen、惠氏及其他子公司独立名下文献。
Review evidenceFound a wrong attribution or number? Tell us